| [1] |
Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update[EB/OL]. [2012-12-20]. http: / /www. asco. org/ASCOv2/Practice +% 26 + Guidelines/Guidelines/Clinical + Practice +Guidelines/Breast+Cancer+Follow-Up+and+Management+After+Primary+Treatment% 3A+American+Society+of+Clinical+Oncology+Clinical+Practice+Guideline+Update.
|
| [2] |
Spratt JS,Donegan WL. Follow-up after treatment of breast cancer[M]/ / Donegan WL, Spratt JS. Cancer of the breast.5th ed. Philadelphia: Saunders,2002: 757-761.
|
| [3] |
Smith TJ, Heddinger S. Medically appropriate follow-up of breast and lung cancer patients[M]/ / ASCO. 2002 ASCO annual meeting educational book. Alexandria: American Society of Clinical Oncology,2002: 652-657. [2012-12-20].http: / /www. asco. org/ascov2/Education + & + Training/Educational+Book? &vmview = edbk_detail_view&confID =16&abstractID=652.
|
| [4] |
Bonadonna G, Moliterni A, Zambetti M, et al. 30 years'follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study[J]. BMJ,2005,330(7485): 217.
|
| [5] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG),Davies C,Godwin J,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials[J]. Lancet,2011,378(9793): 771-784.
|
| [6] |
Palmieria C, Jones A. The 2011 EBCTCG polychemotherapy overview[J]. Lancet,2012,379(9814): 390-392.
|
| [7] |
Tomin R, Donegan WL. Screening for recurrent breast cancer--its effectiveness and prognostic value[J].J Clin Oncol,1987,5(1): 62-67.
|
| [8] |
Palli D, Russo A, Saieva C, et al. Intensive vs clinical followup after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up[J]. JAMA,1999,281(17): 1586.
|
| [9] |
Joseph E, Hyacinthe M, Lyman GH, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer[J]. Ann Surg Oncol,1998,5(6): 522-528,
|
| [10] |
The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial[J]. JAMA 1994,271(20): 1587-1592..
|
| [11] |
Rosselli Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow-up[J]. JAMA,1994,271(20): 1593-1597.
|
| [12] |
Hortobagyi GN. Can we cure limited metastatic breast cancer?[J]. J Clin Oncol,2002,20(3): 620-623.
|
| [13] |
de Bock GH, Bonnema J, van der Hage J, et al. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review[J]. J Clin Oncol,2004,22(19): 4010-4018.
|
| [14] |
Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? [J]. Clin Chem,2006,52(2): 345-351.
|